United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2017

Publisher Name :
Date: 21-Nov-2017
No. of pages: 113
Inquire Before Buying

In this report, the United States B-Cell Maturation Antigen(BCMA) Targeted Therapies market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

- The West

- Southwest

- The Middle Atlantic

- New England

- The South

- The Midwest

with sales (volume), revenue (value), market share and growth rate of B-Cell Maturation Antigen(BCMA) Targeted Therapies in these regions, from 2012 to 2022 (forecast).

United States B-Cell Maturation Antigen(BCMA) Targeted Therapies market competition by top manufacturers/players, with B-Cell Maturation Antigen(BCMA) Targeted Therapies sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

- Transposagen Biopharmaceuticals

- Sutro Biopharma

- Malin Corporation

- Eureka Therapeutics

- firstVentury Equity

- Five Prime Therapeutics

- Credit Suisse Securities

- Dana-Farber Cancer Institute

- Deerfield Partners

- Onyx Pharmaceuticals

- Juno Therapeutics

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

- Bispecific Antibodies

- Antibody Drug Conjugates

- Chimeric Antigen Receptor T-Cells

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

- Liver Cancer

- Respiratory Cancer

- Brain Cancer

- Others

If you have any special requirements, please let us know and we will offer you the report as you want.

United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2017

Table of Contents
United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Report 2017
1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Overview
1.1 Product Overview and Scope of B-Cell Maturation Antigen(BCMA) Targeted Therapies
1.2 Classification of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Product Category
1.2.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Bispecific Antibodies
1.2.4 Antibody Drug Conjugates
1.2.5 Chimeric Antigen Receptor T-Cells
1.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Application/End Users
1.3.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Liver Cancer
1.3.3 Respiratory Cancer
1.3.4 Brain Cancer
1.3.5 Others
1.4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Region
1.4.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
1.4.3 Southwest B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
1.4.5 New England B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
1.4.6 The South B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
1.4.7 The Midwest B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of B-Cell Maturation Antigen(BCMA) Targeted Therapies (2012-2022)
1.5.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2022)
1.5.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate (2012-2022)
2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Competition by Players/Suppliers
2.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Average Price by Players/Suppliers (2012-2017)
2.4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Competitive Situation and Trends
2.4.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Rate
2.4.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers B-Cell Maturation Antigen(BCMA) Targeted Therapies Manufacturing Base Distribution, Sales Area, Product Type
3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Region (2012-2017)
3.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Market Share by Region (2012-2017)
3.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price by Region (2012-2017)
4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Market Share by Type (2012-2017)
4.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price by Type (2012-2017)
4.4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Type (2012-2017)
5 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (Volume) by Application (2012-2017)
5.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Application (2012-2017)
5.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Players/Suppliers Profiles and Sales Data
6.1 Transposagen Biopharmaceuticals
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Sutro Biopharma
6.2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Malin Corporation
6.3.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Eureka Therapeutics
6.4.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 firstVentury Equity
6.5.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Five Prime Therapeutics
6.6.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Credit Suisse Securities
6.7.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Dana-Farber Cancer Institute
6.8.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Deerfield Partners
6.9.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Onyx Pharmaceuticals
6.10.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Juno Therapeutics
7 B-Cell Maturation Antigen(BCMA) Targeted Therapies Manufacturing Cost Analysis
7.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume, Revenue Forecast (2017-2022)
11.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Forecast by Type (2017-2022)
11.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Forecast by Application (2017-2022)
11.4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Forecast by Region (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
List of Tables and Figures
Figure Product Picture of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (K Units) by Type (2012-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Market Share by Type (Product Category) in 2016
Figure Bispecific Antibodies Product Picture
Figure Antibody Drug Conjugates Product Picture
Figure Chimeric Antigen Receptor T-Cells Product Picture
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Application in 2016
Figure Liver Cancer Examples
Table Key Downstream Customer in Liver Cancer
Figure Respiratory Cancer Examples
Table Key Downstream Customer in Respiratory Cancer
Figure Brain Cancer Examples
Table Key Downstream Customer in Brain Cancer
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Million USD) by Region (2012-2022)
Figure The West B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players/Suppliers
Figure 2017 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players/Suppliers
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players/Suppliers
Figure 2017 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players/Suppliers
Table United States Market B-Cell Maturation Antigen(BCMA) Targeted Therapies Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market B-Cell Maturation Antigen(BCMA) Targeted Therapies Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share of Top 3 Players/Suppliers
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers B-Cell Maturation Antigen(BCMA) Targeted Therapies Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Region (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Region (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Region (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Region in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Region (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Region (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Region in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price (USD/Unit) by Region (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Type (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Type (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Type (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Type in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Type (2012-2017)
Figure Revenue Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Type (2012-2017)
Figure Revenue Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Type in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price (USD/Unit) by Types (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Type (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Application (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Application (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Application (2012-2017)
Table Transposagen Biopharmaceuticals Basic Information List
Table Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Sutro Biopharma Basic Information List
Table Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Malin Corporation Basic Information List
Table Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Eureka Therapeutics Basic Information List
Table Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table firstVentury Equity Basic Information List
Table firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Five Prime Therapeutics Basic Information List
Table Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Credit Suisse Securities Basic Information List
Table Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Dana-Farber Cancer Institute Basic Information List
Table Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Deerfield Partners Basic Information List
Table Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Onyx Pharmaceuticals Basic Information List
Table Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Juno Therapeutics Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure Manufacturing Process Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure B-Cell Maturation Antigen(BCMA) Targeted Therapies Industrial Chain Analysis
Table Raw Materials Sources of B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Players/Suppliers in 2016
Table Major Buyers of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Table Distributors/Traders List
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price (USD/Unit) Trend Forecast (2017-2022)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Type in 2022
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Application in 2022
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Share Forecast by Region (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Share Forecast by Region (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global Anti-Fungal Agents Sales Market Report 2017
    Published: 11-Dec-2017        Price: US 4000 Onwards        Pages: 104
    In this report, the global Anti-Fungal Agents market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Anti-Fungal Agents for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japa......
  • Global Smoking Cessation and Nicotine De-Addiction Sales Market Report 2017
    Published: 11-Dec-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Smoking Cessation and Nicotine De-Addiction market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Smoking Cessation and Nicotine De-Addiction for these regions, from 2012 to 2022 (forecast), covering - United S......
  • Global Protein Phosphatase 2A Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Protein Phosphatase 2A market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Protein Phosphatase 2A in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Chin......
  • Global Ectonucleotide Pyrophosphatase Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 108
    In this report, the global Ectonucleotide Pyrophosphatase market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Ectonucleotide Pyrophosphatase in these regions, from 2012 to 2022 (forecast), covering - North America - Euro......
  • Global Meningioma Drug Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Meningioma Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Meningioma Drug in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Jap......
  • Global Gallbladder Cancer Treatment Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Gallbladder Cancer Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Gallbladder Cancer Treatment in these regions, from 2012 to 2022 (forecast), covering - North America - Europe......
  • Global Retinal Vein Occlusion Therapeutics Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Retinal Vein Occlusion Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Retinal Vein Occlusion Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America......
  • Global Urinary Tract Infection (UTI) Drugs Sales Market Report 2017
    Published: 11-Dec-2017        Price: US 4000 Onwards        Pages: 108
    In this report, the global Urinary Tract Infection (UTI) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Urinary Tract Infection (UTI) Drugs for these regions, from 2012 to 2022 (forecast), covering - United States - C......
  • Global Dual Specificity Protein Kinase TTK Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 109
    In this report, the global Dual Specificity Protein Kinase TTK market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Dual Specificity Protein Kinase TTK in these regions, from 2012 to 2022 (forecast), covering - North America......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs